Proposal 3 When crystal induced inflammation occurs the process should be denoted by the name of the underlying condition and the site of the inflammation-that is, arthritis, tendonitis, etc. In routine usage certain terms can be understood for the sake of simplicity. Thus urate gouty bursitis would simply be gouty bursitis and pyrophosphate gouty arthritis would be shortened to pyrophosphate arthritis. Additional adjectives will often be necessary to indicate the specific anatomical location of the response as well as the nature of its coursethat is, acute or chronic. When the role of crystals is uncertain, as is true of the apatite crystals found in many cases of osteoarthritis and in Milwaukee shoulder, most clinicians will probably prefer to retain the present syndrome designations.
Most rheumatic 'diseases' are complex syndromes fashioned out of recurring clinical experience and empirically defined by criteria chosen to select homogeneous groups of patients. Gout has not been an exception to this pattern, and over the years our concepts have broadened and evolved to incorporate more and more aspects of the disease. The most fundamental of these changes, however, has been the acceptance of crystal deposition as the central aspect of this condition.
There is an old saying to the effect that if you don't know where you are going you may not know when you get there. Where we are going in rheumatology is towards a logical understanding of each condition that afflicts our patients. Such understanding requires identification of central pathological factors whose causes and effects can be systematically examined. We do not have such factors for most of the syndromes we encounter, but we do for gout. There, pathological crystals of urate or pyrophosphate, for instance, are as the fundamental to their clinical sequela as the staphylococcus and gonococcus are to septic arthritis. This concept has developed and found wide acceptance over more than 30 years. It now seems appropriate to mark this acceptance by discarding the many and various names that are applied to idiopathic, crystal related syndromes and replacing them with a new terminology that is more consistent, clear, and simple but still pays homage to tradition.
This commentary proposes such a system and invites the constructive responses of those who see room for improvement in the current terminology of gout.
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